BARIATEK-MEDICAL
BariaTek Medical, a privately held medical device company dedicated to the development of minimally invasive endoscopically delivered solutions to treat obesity and diabetes, founded by Truffle Capital, announced it has initiated enrollment of patients in its First-in-human clinical trial in both Australia and Uzbekistan, and has successfully performed its first-in-human implantation.
Obesity is a chronic and debilitating disease affecting more than one billion people worldwide. It bears a tremendous economic burden to healthcare systems surpassing that of cardiovascular diseases and cancer and its prevalence is increasing worldwide. It often leads to diabetes, high blood pressure, heart disease and reduced life expectancy.
Bariatric surgery currently remains the most effective approach to treat obesity and limits the resulting complications, but surgery is poorly perceived, alters anatomy permanently, is costly, and can result in severe adverse events. Obesity pharmaceutical therapies could provide an effective alternative solution for some patients, but they are very expensive and poorly tolerated in many, resulting in their cessation and corresponding regain of the lost weight. Furthermore, they could be associated with multiple under-reported side-effects and off-label prescriptions. As for available minimally invasive endoscopic solutions, they enjoy variable safety but lack efficacy.
BariaTek Medical’s product candidate, the BariTon™, is a soft, atraumatic, reversible implant that is delivered via a simple endoscopy through the mouth within a few minutes and in an outpatient setting. It consists of a gastric part and an intestinal part, thereby having a dual effect: reduced food intake and calorie absorption. The BariTon™ is expected to be the first implant of its kind to potentially mimic the efficacy of sleeve gastrectomy and bypass surgery1 and offer superior safety, ease of use, reversibility, and lower cost.
Dr. Abdurashid Abdukarimov, Principal Investigator, Bariatric Surgeon at the Center of Surgery in Tashkent Uzbekistan who has led the first human implant said: “I am extremely pleased with the outcome of this first-in-human implantation. The endoscopic procedure was smooth, and the patient recovered very rapidly. She was back at work the day after she was discharged. I would like to thank the support of the BariaTek medical and engineering team, who made the trip to our center, and we look forward to the next steps in this groundbreaking first-in-human study.”
Dr. Adrian Sartoretto, Principal Investigator, Bariatric Endoscopist and Director of the BMI Clinic in Sydney Australia said: “The daily life of patients suffering from obesity can be difficult and associated with multiple comorbidities if not treated optimally. The BariTon™ device meets a growing demand for a more innovative, minimally invasive, effective, and reversible solution and we look forward to evaluating its safety and efficacy in our center.”
Dr. Thierry Manos and Dr. Christophe Bastid (Marseilles, France), Bariatric Endoscopists and co-inventors of the BariTon™ said: “We were delighted to participate in this first-in-human implantation. The procedure went according to plan and we look forward to the outcome of this clinical study.”
Youssef Biadillah, CEO of BariaTek Medical said: “Obesity is a global pandemic and none of the therapeutic options available today is optimal. We are thrilled about the prospect of bringing our highly differentiated solution, the BariTon™, to obesity gastroenterologists and surgeons and to patients worldwide. More patients need to be treated and carefully monitored and close interactions with regulatory agencies and payors need to take place, to draw conclusions on its safety, efficacy, indications and market potential.”
About BariaTek Medical
BariaTek Medical, based in Paris France, is a privately held medical device company dedicated to the development of minimally invasive endoscopically delivered medical devices to treat obesity and limit its complications. BariaTek Medical was founded by Truffle Capital, a premier life science venture capital fund (Paris) and founder (or co-founder) of multiple MedTech and Biotech companies such as Abivax (NASDAQ & Euronext : ABVX), Carmat (Euronext: ALCAR), Carbios (Euronext ALCRB), Vexim (acquired by Stryker), Symetis (acquired by Boston Scientific), Caranx Medical, Artedrone, EvextaBio and Affluent Medical (Euronext: AFME).
1 Sleeve gastrectomy is a surgical procedure consists of removing a large part of the stomach; Bypass bariatric surgery consists of both removing a large part of the stomach and shunting part of the intestine.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240206231942/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update8.12.2024 18:52:00 CET | Press release
- Data from long-term follow-up of patients in clinical trials further demonstrate durability of the transformative benefits of CASGEVY™ - - Safety profile consistent with busulfan conditioning andautologous hematopoietic stem cell transplant -- Vertex provides update on progress in bringing CASGEVY to patients - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY™ (exagamglogene autotemcel) from global clinical trials in people with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). CASGEVY is the first and only approved CRISPR/Cas9 gene-edited therapy. The results, presented at the American Society of Hematology (ASH) Annual Meeting and Exposition, continue to demonstrate the transformative, durable clinical benefits of CASGEVY. The longest follow up for both SCD and TDT patients now extends more than 5 years, with a median of 33.2 months and 38.1 months, respectively. “These comprehensive data provide additio
Andersen Global indvier medlemsvirksomhed i Caribien7.12.2024 01:02:00 CET | Pressemeddelelse
Andersen Global fortsætter med at sætte sit aftryk på det globale landskab, når Robley Baynes, en samarbejdsvirksomhed siden 2020, nu bliver medlemsvirksomhed og tager Andersen-navnet. Andersen in Trinidad and Tobago er den første medlemsvirksomhed i Caribien, der iklæder sig Andersen-brandet i regionen og styrker organisationens globale rækkevidde yderligere. Med partnerne Kendell Robley og Mikhail Baynes som ledere arbejder Andersen in Trinidad and Tobago tæt sammen med kunderne om at levere kvalitetsservice inden for skat, rådgivning, økonomi, selskabsspørgsmål og ledelse. Firmaets kundefokuserede forretningsmodel sikrer integrerede kvalitetsløsninger, der er skræddersyet til at imødekomme de voksende globale krav. "Vores firma har udviklet sig enormt gennem årene, og vores team arbejder flittigt på at levere integrerede kvalitetsløsninger i et forretningslandskab i stadig udvikling," siger Kendell og Mikhail. "Ved at blive medlem af Andersen Global har vi forpligtet os på at drive
Andersen Global styrker sin tilstedeværelse i Malta med endnu en medlemsvirksomhed6.12.2024 23:28:00 CET | Pressemeddelelse
Andersen Global fortsætter med at styrke sin tilstedeværelse i Europa gennem etableringen af Andersen in Malta. Sammen med den eksisterende medlemsadvokatvirksomhed Chetcuti Cauchi Advocates vil der kunne leveres en omfattende pakke af integrerede skattemæssige, juridiske og virksomhedstjenester til private og erhvervskunder i Malta og internationalt. Andersen in Malta leverer en bred vifte af tjenester, herunder skatterådgivning for personer og virksomheder og sikring af deres efterrettelighed vedrørende skatteregler, transfer pricing, dataoverholdelse, global mobilitet og immigration af privatpersoner med stor nettoformue (HNW), ejendomsplanlægning, privat formue-strukturering, rådgivning af familievirksomheder og andre virksomheder. Andersen in Malta har specialiseret sig i at navigere i komplekse regulerings- og skatterammer og rådgiver HNW-personer, familiekontorer og multinationale virksomheder. "I takt med at Malta udvikler sig som en pålidelig destination for privat formue-stru
Lattice Wins 2024 Global Semiconductor Alliance Award6.12.2024 22:00:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $500 Million to $1 Billion in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2024 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their vision, innovation, execution, and future opportunity, as determined by votes from GSA members. “On behalf of the entire team at Lattice, I am honored to accept this prestigious award from the GSA. I am incredibly proud to lead such a talented and dedicated group of individuals who continuously strive to innovate and exceed our customers' expectations. This achievement would not have been possible without the support of our customers and partners. Thank you for being an essential part of our journey,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. “The GSA congratulates
Greenland Resources Welcomes Canada’s Decision to Open a Consulate in Greenland6.12.2024 20:07:00 CET | Press release
Greenland Resources Inc. (Cboe CA: MOLY | FSE: M0LY) (“Greenland Resources” or the “Company”) welcomes the Government of Canada’s decision announced today to appoint an Arctic ambassador and open a consulate in Nuuk, Greenland. This follows the new Canadian Arctic Foreign Policy Framework to protect, together with its allies, the economic and military challenges including mineral resources security supply in the Arctic. The Company believes this is relevant for the Project as it is in negotiations to secure Capex funding from Canadian and recently announced European financial institutions and agencies in its press releases dated October 1 and October 15, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241206778181/en/ Greenland Resources Inc. Greenland Resources is a Canadian public company with the Ontario Securities Commission as its principal regulator and is focused on the development of its 100% owned Climax type p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom